Trial Profile
Prospective, Multicenter, Randomized, Double-blind, Controlled Parallel Group Study Designed to Assess the Risk-benefit Balance of the Gradual Withdrawal of a Calcineurin Inhibitor (Tacrolimus) in Renal Transplant Patients Over 4 Years and Clinically Selected
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 01 Jul 2016 Results published in the American Journal of Transplantation
- 22 Mar 2016 Status changed from active, no longer recruiting to discontinued due to difficulties of recruitment as reported by ClinicalTrials.gov,
- 05 Sep 2012 Planned End Date changed from 1 Jan 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.